Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 371.55 INR 4.32%
Market Cap: 186.8B INR

Intrinsic Value

The intrinsic value of one ERIS stock under the Base Case scenario is 1 158.46 INR. Compared to the current market price of 1 371.55 INR, Eris Lifesciences Ltd is Overvalued by 16%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ERIS Intrinsic Value
1 158.46 INR
Overvaluation 16%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Eris Lifesciences Ltd

ERIS
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for ERIS cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Eris Lifesciences Ltd
NSE:ERIS
IN
Pharmaceuticals
Market Cap
186.6B INR
IPO
Jun 29, 2017
IN
Pharmaceuticals
Market Cap
186.6B INR
IPO
Jun 29, 2017
Price
â‚ąfalse
EPS
â‚ąfalse
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ERIS?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Eris Lifesciences Ltd
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Eris Lifesciences Ltd

Current Assets 13.2B
Cash & Short-Term Investments 1.9B
Receivables 5.7B
Other Current Assets 5.6B
Non-Current Assets 57B
Long-Term Investments 520.9m
PP&E 5.2B
Intangibles 47.8B
Other Non-Current Assets 3.5B
Efficiency

Free Cash Flow Analysis
Eris Lifesciences Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Eris Lifesciences Ltd

Revenue
27.4B INR
Cost of Revenue
-6.6B INR
Gross Profit
20.8B INR
Operating Expenses
-14.6B INR
Operating Income
6.2B INR
Other Expenses
-2.9B INR
Net Income
3.3B INR
Fundamental Scores

ERIS Profitability Score
Profitability Due Diligence

Eris Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Positive Operating Income
62/100
Profitability
Score

Eris Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

ERIS Solvency Score
Solvency Due Diligence

Eris Lifesciences Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
48/100
Solvency
Score

Eris Lifesciences Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ERIS Price Targets Summary
Eris Lifesciences Ltd

Wall Street analysts forecast ERIS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ERIS is 1 531.66 INR with a low forecast of 1 282.7 INR and a high forecast of 1 785 INR.

Lowest
Price Target
1 282.7 INR
6% Downside
Average
Price Target
1 531.66 INR
12% Upside
Highest
Price Target
1 785 INR
30% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ERIS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ERIS Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ERIS stock?

The intrinsic value of one ERIS stock under the Base Case scenario is 1 158.46 INR.

Is ERIS stock undervalued or overvalued?

Compared to the current market price of 1 371.55 INR, Eris Lifesciences Ltd is Overvalued by 16%.

Back to Top